Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 905

1.

Sarcopenia: A Time for Action. An SCWD Position Paper.

Bauer J, Morley JE, Schols AMWJ, Ferrucci L, Cruz-Jentoft AJ, Dent E, Baracos VE, Crawford JA, Doehner W, Heymsfield SB, Jatoi A, Kalantar-Zadeh K, Lainscak M, Landi F, Laviano A, Mancuso M, Muscaritoli M, Prado CM, Strasser F, von Haehling S, Coats AJS, Anker SD.

J Cachexia Sarcopenia Muscle. 2019 Sep 15. doi: 10.1002/jcsm.12483. [Epub ahead of print]

2.

Evaluation of the effects of sodium-glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality in patients with chronic heart failure and a preserved ejection fraction: rationale for and design of the EMPEROR-Preserved Trial.

Anker SD, Butler J, Filippatos GS, Jamal W, Salsali A, Schnee J, Kimura K, Zeller C, George J, Brueckmann M, Zannad F, Packer M; EMPEROR-Preserved Trial Committees and Investigators.

Eur J Heart Fail. 2019 Sep 16. doi: 10.1002/ejhf.1596. [Epub ahead of print]

PMID:
31523904
3.

Redefining Heart Failure With a Reduced Ejection Fraction.

Butler J, Anker SD, Packer M.

JAMA. 2019 Sep 13. doi: 10.1001/jama.2019.15600. [Epub ahead of print] No abstract available.

PMID:
31517955
4.

How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).

Pieske B, Tschöpe C, de Boer RA, Fraser AG, Anker SD, Donal E, Edelmann F, Fu M, Guazzi M, Lam CSP, Lancellotti P, Melenovsky V, Morris DA, Nagel E, Pieske-Kraigher E, Ponikowski P, Solomon SD, Vasan RS, Rutten FH, Voors AA, Ruschitzka F, Paulus WJ, Seferovic P, Filippatos G.

Eur Heart J. 2019 Aug 31. pii: ehz641. doi: 10.1093/eurheartj/ehz641. [Epub ahead of print]

PMID:
31504452
5.

A comprehensive analysis of the effects of rivaroxaban on stroke or transient ischaemic attack in patients with heart failure, coronary artery disease, and sinus rhythm: the COMMANDER HF trial

Mehra MR, Vaduganathan M, Fu M, Ferreira JP, Anker SD, Cleland JGF, Lam CSP, van Veldhuisen DJ, Byra WM, Spiro TE, Deng H, Zannad F, Greenberg B.

Eur Heart J. 2019 Jun 25. doi: 10.1093/eurheartj/ehz427. [Epub ahead of print]

PMID:
31461239
6.

The Journal of Cachexia, Sarcopenia and Muscle in 2019.

von Haehling S, Ebner N, Anker SD.

J Cachexia Sarcopenia Muscle. 2019 Aug;10(4):715-720. doi: 10.1002/jcsm.12482. No abstract available.

7.

Identifying optimal doses of heart failure medications in men compared with women: a prospective, observational, cohort study.

Santema BT, Ouwerkerk W, Tromp J, Sama IE, Ravera A, Regitz-Zagrosek V, Hillege H, Samani NJ, Zannad F, Dickstein K, Lang CC, Cleland JG, Ter Maaten JM, Metra M, Anker SD, van der Harst P, Ng LL, van der Meer P, van Veldhuisen DJ, Meyer S, Lam CSP; ASIAN-HF investigators, Voors AA.

Lancet. 2019 Aug 22. pii: S0140-6736(19)31792-1. doi: 10.1016/S0140-6736(19)31792-1. [Epub ahead of print]

PMID:
31447116
8.

Patient Discharge Instructions in the Emergency Department and Their Effects on Comprehension and Recall of Discharge Instructions: A Systematic Review and Meta-analysis.

Hoek AE, Anker SCP, van Beeck EF, Burdorf A, Rood PPM, Haagsma JA.

Ann Emerg Med. 2019 Aug 19. pii: S0196-0644(19)30498-6. doi: 10.1016/j.annemergmed.2019.06.008. [Epub ahead of print]

PMID:
31439363
9.

Effects of Serelaxin in Patients with Acute Heart Failure.

Metra M, Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Pang PS, Ponikowski P, Voors AA, Adams KF, Anker SD, Arias-Mendoza A, Avendaño P, Bacal F, Böhm M, Bortman G, Cleland JGF, Cohen-Solal A, Crespo-Leiro MG, Dorobantu M, Echeverría LE, Ferrari R, Goland S, Goncalvesová E, Goudev A, Køber L, Lema-Osores J, Levy PD, McDonald K, Manga P, Merkely B, Mueller C, Pieske B, Silva-Cardoso J, Špinar J, Squire I, Stępińska J, Van Mieghem W, von Lewinski D, Wikström G, Yilmaz MB, Hagner N, Holbro T, Hua TA, Sabarwal SV, Severin T, Szecsödy P, Gimpelewicz C; RELAX-AHF-2 Committees Investigators.

N Engl J Med. 2019 Aug 22;381(8):716-726. doi: 10.1056/NEJMoa1801291.

PMID:
31433919
10.

Geographical location affects the levels and association of trimethylamine N-oxide with heart failure mortality in BIOSTAT-CHF: a post-hoc analysis.

Yazaki Y, Salzano A, Nelson CP, Voors AA, Anker SD, Cleland JG, Lang CC, Metra M, Samani NJ, Ng LL, Suzuki T.

Eur J Heart Fail. 2019 Jul 28. doi: 10.1002/ejhf.1550. [Epub ahead of print] No abstract available.

PMID:
31353762
11.

Heart failure prevalence in the general population: SOBOTA-HF study rationale and design.

Lainscak M, Omersa D, Sedlar N, Anker SD, Farkas J.

ESC Heart Fail. 2019 Jul 25. doi: 10.1002/ehf2.12496. [Epub ahead of print]

12.

The influence of atrial fibrillation on the levels of NT-proBNP versus GDF-15 in patients with heart failure.

Santema BT, Chan MMY, Tromp J, Dokter M, van der Wal HH, Emmens JE, Takens J, Samani NJ, Ng LL, Lang CC, van der Meer P, Ter Maaten JM, Damman K, Dickstein K, Cleland JG, Zannad F, Anker SD, Metra M, van der Harst P, de Boer RA, van Veldhuisen DJ, Rienstra M, Lam CSP, Voors AA.

Clin Res Cardiol. 2019 Jul 1. doi: 10.1007/s00392-019-01513-y. [Epub ahead of print]

PMID:
31263996
13.

Pathophysiology, diagnosis and management of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Study Group on peripartum cardiomyopathy.

Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, Hamdan R, Jackson AM, Forsyth P, de Boer RA, Mueller C, Lyon AR, Lund LH, Piepoli MF, Heymans S, Chioncel O, Anker SD, Ponikowski P, Seferovic PM, Johnson MR, Mebazaa A, Sliwa K.

Eur J Heart Fail. 2019 Jul;21(7):827-843. doi: 10.1002/ejhf.1493. Epub 2019 Jun 27.

PMID:
31243866
14.

Rationale and design of the EMPERIAL-Preserved and EMPERIAL-Reduced trials of empagliflozin in patients with chronic heart failure.

Abraham WT, Ponikowski P, Brueckmann M, Zeller C, Macesic H, Peil B, Brun M, Ustyugova A, Jamal W, Salsali A, Lindenfeld J, Anker SD; EMPERIAL Investigators and National Coordinators.

Eur J Heart Fail. 2019 Jul;21(7):932-942. doi: 10.1002/ejhf.1486. Epub 2019 Jun 19.

PMID:
31218819
15.

Mid-regional pro-atrial natriuretic peptide for the early detection of non-acute heart failure.

Gohar A, Rutten FH, den Ruijter H, Kelder JC, von Haehling S, Anker SD, Möckel M, Hoes AW.

Eur J Heart Fail. 2019 Jun 17. doi: 10.1002/ejhf.1495. [Epub ahead of print]

PMID:
31209992
16.

Differences in Clinical Profile and Outcomes of Low Iron Storage vs Defective Iron Utilization in Patients With Heart Failure: Results From the DEFINE-HF and BIOSTAT-CHF Studies.

Grote Beverborg N, van der Wal HH, Klip IT, Anker SD, Cleland J, Dickstein K, van Veldhuisen DJ, Voors AA, van der Meer P.

JAMA Cardiol. 2019 Jul 1;4(7):696-701. doi: 10.1001/jamacardio.2019.1739.

PMID:
31188392
17.

Effect of ferric carboxymaltose on calculated plasma volume status and clinical congestion: a FAIR-HF substudy.

Okonko DO, Jouhra F, Abu-Own H, Filippatos G, Colet JC, Suki C, Mori C, Ponikowski P, Anker SD; FAIR-HF Investigators.

ESC Heart Fail. 2019 Aug;6(4):621-628. doi: 10.1002/ehf2.12462. Epub 2019 May 30.

18.

Sacubitril/valsartan eligibility and outcomes in the ESC-EORP-HFA Heart Failure Long-Term Registry: bridging between European Medicines Agency/Food and Drug Administration label, the PARADIGM-HF trial, ESC guidelines, and real world.

Kapelios CJ, Lainscak M, Savarese G, Laroche C, Seferovic P, Ruschitzka F, Coats A, Anker SD, Crespo-Leiro MG, Filippatos G, Piepoli MF, Rosano G, Zanolla L, Aguiar C, Murin J, Leszek P, McDonagh T, Maggioni AP, Lund LH; HF-LT Registry Investigators Group.

Eur J Heart Fail. 2019 May 27. doi: 10.1002/ejhf.1532. [Epub ahead of print]

PMID:
31132222
19.

The AFR-PRELIEVE trial: a prospective, non-randomised, pilot study to assess the Atrial Flow Regulator (AFR) in heart failure patients with either preserved or reduced ejection fraction.

Paitazoglou C, Özdemir R, Pfister R, Bergmann MW, Bartunek J, Kilic T, Lauten A, Schmeisser A, Zoghi M, Anker S, Sievert H, Mahfoud F.

EuroIntervention. 2019 Aug 29;15(5):403-410. doi: 10.4244/EIJ-D-19-00342.

20.

Biomarker guidance allows a more personalized allocation of patients for remote patient management in heart failure: results from the TIM-HF2 trial.

Möckel M, Koehler K, Anker SD, Vollert J, Moeller V, Koehler M, Gehrig S, Wiemer JC, von Haehling S, Koehler F.

Eur J Heart Fail. 2019 May 25. doi: 10.1002/ejhf.1530. [Epub ahead of print]

PMID:
31129929
21.

Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology.

Seferovic PM, Ponikowski P, Anker SD, Bauersachs J, Chioncel O, Cleland JGF, de Boer RA, Drexel H, Ben Gal T, Hill L, Jaarsma T, Jankowska EA, Anker MS, Lainscak M, Lewis BS, McDonagh T, Metra M, Milicic D, Mullens W, Piepoli MF, Rosano G, Ruschitzka F, Volterrani M, Voors AA, Filippatos G, Coats AJS.

Eur J Heart Fail. 2019 May 26. doi: 10.1002/ejhf.1531. [Epub ahead of print]

PMID:
31129923
22.

Pharmacy-based interdisciplinary intervention for patients with chronic heart failure: results of the PHARM-CHF randomized controlled trial.

Schulz M, Griese-Mammen N, Anker SD, Koehler F, Ihle P, Ruckes C, Schumacher PM, Trenk D, Böhm M, Laufs U; PHARM-CHF Investigators.

Eur J Heart Fail. 2019 Aug;21(8):1012-1021. doi: 10.1002/ejhf.1503. Epub 2019 Jun 7.

PMID:
31129917
23.

Proenkephalin, an Opioid System Surrogate, as a Novel Comprehensive Renal Marker in Heart Failure.

Emmens JE, Ter Maaten JM, Damman K, van Veldhuisen DJ, de Boer RA, Struck J, Bergmann A, Sama IE, Streng KW, Anker SD, Dickstein K, Lang CC, Metra M, Samani NJ, Ng LL, Voors AA.

Circ Heart Fail. 2019 May;12(5):e005544. doi: 10.1161/CIRCHEARTFAILURE.118.005544.

PMID:
31091993
24.

The clinical significance of interleukin-6 in heart failure: results from the BIOSTAT-CHF study.

Markousis-Mavrogenis G, Tromp J, Ouwerkerk W, Devalaraja M, Anker SD, Cleland JG, Dickstein K, Filippatos GS, van der Harst P, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, Zannad F, Zwinderman AH, Hillege HL, van Veldhuisen DJ, Kakkar R, Voors AA, van der Meer P.

Eur J Heart Fail. 2019 Aug;21(8):965-973. doi: 10.1002/ejhf.1482. Epub 2019 May 14.

PMID:
31087601
25.

Heart failure in chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference.

House AA, Wanner C, Sarnak MJ, Piña IL, McIntyre CW, Komenda P, Kasiske BL, Deswal A, deFilippi CR, Cleland JGF, Anker SD, Herzog CA, Cheung M, Wheeler DC, Winkelmayer WC, McCullough PA; Conference Participants.

Kidney Int. 2019 Jun;95(6):1304-1317. doi: 10.1016/j.kint.2019.02.022. Epub 2019 Apr 30.

26.

Association of Rivaroxaban With Thromboembolic Events in Patients With Heart Failure, Coronary Disease, and Sinus Rhythm: A Post Hoc Analysis of the COMMANDER HF Trial.

Greenberg B, Neaton JD, Anker SD, Byra WM, Cleland JGF, Deng H, Fu M, La Police DA, Lam CSP, Mehra MR, Nessel CC, Spiro TE, van Veldhuisen DJ, Vanden Boom CM, Zannad F.

JAMA Cardiol. 2019 Jun 1;4(6):515-523. doi: 10.1001/jamacardio.2019.1049.

PMID:
31017637
27.

The evolving obesity paradigm story: from heart failure to atrial fibrillation.

von Haehling S, Doehner W, Anker SD.

Eur Heart J. 2019 May 14;40(19):1550-1552. doi: 10.1093/eurheartj/ehz082. No abstract available.

PMID:
31009055
28.

Novel potassium binders as enabling therapy in heart failure.

Butler J, Khan MS, Anker SD.

Eur J Heart Fail. 2019 May;21(5):550-552. doi: 10.1002/ejhf.1474. Epub 2019 Apr 16. No abstract available.

PMID:
30993820
29.

Heart failure in cardiomyopathies: a position paper from the Heart Failure Association of the European Society of Cardiology.

Seferović PM, Polovina M, Bauersachs J, Arad M, Gal TB, Lund LH, Felix SB, Arbustini E, Caforio ALP, Farmakis D, Filippatos GS, Gialafos E, Kanjuh V, Krljanac G, Limongelli G, Linhart A, Lyon AR, Maksimović R, Miličić D, Milinković I, Noutsias M, Oto A, Oto Ö, Pavlović SU, Piepoli MF, Ristić AD, Rosano GMC, Seggewiss H, Ašanin M, Seferović JP, Ruschitzka F, Čelutkiene J, Jaarsma T, Mueller C, Moura B, Hill L, Volterrani M, Lopatin Y, Metra M, Backs J, Mullens W, Chioncel O, de Boer RA, Anker S, Rapezzi C, Coats AJS, Tschöpe C.

Eur J Heart Fail. 2019 May;21(5):553-576. doi: 10.1002/ejhf.1461. Epub 2019 Apr 16.

PMID:
30989768
30.

Sympatho-Vagal Imbalance is Associated with Sarcopenia in Male Patients with Heart Failure.

Fonseca GWPD, Santos MRD, Souza FR, Costa MJAD, Haehling SV, Takayama L, Pereira RMR, Negrão CE, Anker SD, Alves MJNN.

Arq Bras Cardiol. 2019 Jun;112(6):739-746. doi: 10.5935/abc.20190061. Epub 2019 Apr 8. English, Portuguese.

31.

Physicians' guideline adherence is associated with long-term heart failure mortality in outpatients with heart failure with reduced ejection fraction: the QUALIFY international registry.

Komajda M, Schöpe J, Wagenpfeil S, Tavazzi L, Böhm M, Ponikowski P, Anker SD, Filippatos GS, Cowie MR; QUALIFY Investigators.

Eur J Heart Fail. 2019 Jul;21(7):921-929. doi: 10.1002/ejhf.1459. Epub 2019 Apr 1.

PMID:
30933403
32.

Orphan disease status of cancer cachexia in the USA and in the European Union: a systematic review.

Anker MS, Holcomb R, Muscaritoli M, von Haehling S, Haverkamp W, Jatoi A, Morley JE, Strasser F, Landmesser U, Coats AJS, Anker SD.

J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):22-34. doi: 10.1002/jcsm.12402.

33.

Recent developments in the field of cachexia, sarcopenia, and muscle wasting: highlights from the 11th Cachexia Conference.

Ebner N, Anker SD, von Haehling S.

J Cachexia Sarcopenia Muscle. 2019 Feb;10(1):218-225. doi: 10.1002/jcsm.12408.

34.

ESC e-Cardiology Working Group Position Paper: Overcoming challenges in digital health implementation in cardiovascular medicine.

Frederix I, Caiani EG, Dendale P, Anker S, Bax J, Böhm A, Cowie M, Crawford J, de Groot N, Dilaveris P, Hansen T, Koehler F, Krstačić G, Lambrinou E, Lancellotti P, Meier P, Neubeck L, Parati G, Piotrowicz E, Tubaro M, van der Velde E.

Eur J Prev Cardiol. 2019 Jul;26(11):1166-1177. doi: 10.1177/2047487319832394. Epub 2019 Mar 27.

35.

Novel biomarkers in heart failure and cardio-oncology.

Anker MS, von Haehling S, Anker SD.

Kardiol Pol. 2019;77(3):329-330. doi: 10.5603/KP.2019.0051. No abstract available.

36.

Remote monitoring of implantable cardioverter-defibrillators and resynchronization devices to improve patient outcomes: dead end or way ahead?

Braunschweig F, Anker SD, Proff J, Varma N.

Europace. 2019 Jun 1;21(6):846-855. doi: 10.1093/europace/euz011.

37.

Mode-of-action of the PROPELLA concept in fulminant myocarditis.

Spillmann F, Van Linthout S, Schmidt G, Klein O, Hamdani N, Mairinger T, Krackhardt F, Maroski B, Schlabs T, Soltani S, Anker S, Potapov EV, Burkhoff D, Pieske B, Tschöpe C.

Eur Heart J. 2019 Jul 1;40(26):2164-2169. doi: 10.1093/eurheartj/ehz124.

38.

Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure.

Ter Maaten JM, Kremer D, Demissei BG, Struck J, Bergmann A, Anker SD, Ng LL, Dickstein K, Metra M, Samani NJ, Romaine SPR, Cleland J, Girerd N, Lang CC, van Veldhuisen DJ, Voors AA.

Eur J Heart Fail. 2019 Jun;21(6):732-743. doi: 10.1002/ejhf.1437. Epub 2019 Mar 6.

PMID:
30843353
39.

New treatments for hyperkalaemia: clinical use in cardiology.

Vijayakumar S, Butler J, Anker SD.

Eur Heart J Suppl. 2019 Feb;21(Suppl A):A41-A47. doi: 10.1093/eurheartj/suy031. Epub 2019 Feb 26.

40.

Association between mortality and implantable cardioverter-defibrillators by aetiology of heart failure: a propensity-matched analysis of the WARCEF trial.

Lee TC, Qian M, Mu L, Di Tullio MR, Graham S, Mann DL, Nakanishi K, Teerlink JR, Lip GYH, Freudenberger RS, Sacco RL, Mohr JP, Labovitz AJ, Ponikowski P, Lok DJ, Estol C, Anker SD, Pullicino PM, Buchsbaum R, Levin B, Thompson JLP, Homma S, Ye S; WARCEF Investigators.

ESC Heart Fail. 2019 Apr;6(2):297-307. doi: 10.1002/ehf2.12407. Epub 2019 Feb 27.

41.

Pulse pressure and prognosis in patients with heart failure with reduced ejection fraction.

Shah N, Qian M, Di Tullio MR, Graham S, Mann DL, Sacco RL, Lip GYH, Labovitz AJ, Ponikowski P, Lok DJ, Anker SD, Teerlink JR, Thompson JLP, Homma S, Freudenberger RS; WARCEF Investigators.

Eur J Clin Invest. 2019 Feb 23:e13092. doi: 10.1111/eci.13092. [Epub ahead of print]

PMID:
30801690
42.

Body weight changes and incidence of cachexia after stroke.

Scherbakov N, Pietrock C, Sandek A, Ebner N, Valentova M, Springer J, Schefold JC, von Haehling S, Anker SD, Norman K, Haeusler KG, Doehner W.

J Cachexia Sarcopenia Muscle. 2019 Jun;10(3):611-620. doi: 10.1002/jcsm.12400. Epub 2019 Jan 24.

43.

Cardiac contractility modulation improves long-term survival and hospitalizations in heart failure with reduced ejection fraction.

Anker SD, Borggrefe M, Neuser H, Ohlow MA, Röger S, Goette A, Remppis BA, Kuck KH, Najarian KB, Gutterman DD, Rousso B, Burkhoff D, Hasenfuss G.

Eur J Heart Fail. 2019 Sep;21(9):1103-1113. doi: 10.1002/ejhf.1374. Epub 2019 Jan 16.

PMID:
30652394
44.

Prognostic significance of changes in heart rate following uptitration of beta-blockers in patients with sub-optimally treated heart failure with reduced ejection fraction in sinus rhythm versus atrial fibrillation.

Mordi IR, Santema BT, Kloosterman M, Choy AM, Rienstra M, van Gelder I, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Metra M, Ng LL, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zwinderman AH, Zannad F, Voors AA, Lang CC.

Clin Res Cardiol. 2019 Jul;108(7):797-805. doi: 10.1007/s00392-018-1409-x. Epub 2019 Jan 4.

45.

Clinical correlates and outcome associated with changes in 6-minute walking distance in patients with heart failure: findings from the BIOSTAT-CHF study.

Ferreira JP, Metra M, Anker SD, Dickstein K, Lang CC, Ng L, Samani NJ, Cleland JG, van Veldhuisen DJ, Voors AA, Zannad F.

Eur J Heart Fail. 2019 Feb;21(2):218-226. doi: 10.1002/ejhf.1380. Epub 2019 Jan 1.

PMID:
30600578
46.

Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure.

Everett BM, Cornel JH, Lainscak M, Anker SD, Abbate A, Thuren T, Libby P, Glynn RJ, Ridker PM.

Circulation. 2019 Mar 5;139(10):1289-1299. doi: 10.1161/CIRCULATIONAHA.118.038010.

PMID:
30586730
47.

The new Heart Failure Association journal - ESC Heart Failure.

Anker MS, von Haehling S, Papp Z, Anker SD.

Eur J Heart Fail. 2018 Dec;20(12):1657-1663. doi: 10.1002/ejhf.1362. Review. No abstract available.

PMID:
30561163
48.

Iron Deficiency in Heart Failure: An Overview.

von Haehling S, Ebner N, Evertz R, Ponikowski P, Anker SD.

JACC Heart Fail. 2019 Jan;7(1):36-46. doi: 10.1016/j.jchf.2018.07.015. Epub 2018 Dec 12. Review.

PMID:
30553903
49.

Novel endotypes in heart failure: effects on guideline-directed medical therapy.

Tromp J, Ouwerkerk W, Demissei BG, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Ng LL, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, Voors AA, van der Meer P.

Eur Heart J. 2018 Dec 21;39(48):4269-4276. doi: 10.1093/eurheartj/ehy712.

PMID:
30551207
50.

Medication dosing for heart failure with reduced ejection fraction - opportunities and challenges.

Marti CN, Fonarow GC, Anker SD, Yancy C, Vaduganathan M, Greene SJ, Ahmed A, Januzzi JL, Gheorghiade M, Filippatos G, Butler J.

Eur J Heart Fail. 2019 Mar;21(3):286-296. doi: 10.1002/ejhf.1351. Epub 2018 Dec 10. Review.

PMID:
30537163

Supplemental Content

Support Center